Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke. Evidence has demonstrated the important functions of these eicosanoids in regulating cerebral vascular tone, cerebral blood flow, and autoregulation of cerebral circulation. Although COX-2 inhibitors have been suggested as potential treatments for stroke, adverse events, including an increased risk of stroke, occur following long-term use of coxibs. It is important to note that prolonged treatment with rofecoxib increased circulating levels of 20-hydroxyeicosatetraenoic acid (20-HETE), and 20-HETE blockade is a possible strategy to prevent coxib-induced stroke events. It appears that 20-HETE has detrimental effects in the brain, and that its blockade exerts cerebroprotection against ischemic stroke and subarachnoid hemorrhage (SAH). There is clear evidence that activation of EP2 and EP4 receptors exerts cerebroprotection against ischemic stroke. Several elegant studies have contributed to defining the importance of stabilizing the levels of epoxyeicosatrienoic acids (EETs), by inhibiting or deleting soluble epoxide hydrolase (sEH), in stroke research. These reports support the notion that sEH blockade is cerebroprotective against ischemic stroke and SAH. Here, we summarize recent findings implicating these eicosanoid pathways in cerebral vascular function and stroke. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of ischemic stroke and SAH.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalProstaglandins and Other Lipid Mediators
Volume122
DOIs
StatePublished - Jan 1 2016

Fingerprint

Eicosanoids
Prostaglandin-Endoperoxide Synthases
Cytochrome P-450 Enzyme System
Epoxide Hydrolases
Cyclooxygenase 2 Inhibitors
Stroke
Cerebrovascular Circulation
Subarachnoid Hemorrhage
Arachidonic Acid
Brain
Animals
Blood
Genes
Chemical activation
Acids
Blood Vessels
20-hydroxy-5,8,11,14-eicosatetraenoic acid
Gene Deletion
Homeostasis
Cardiovascular Diseases

Keywords

  • Cyclooxygenase
  • Cytochrome P450
  • Eicosanoids
  • Soluble epoxide hydrolase
  • Stroke

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke. / Huang, Hui; Al-Shabrawey, Mohamed; Wang, Mong-Heng.

In: Prostaglandins and Other Lipid Mediators, Vol. 122, 01.01.2016, p. 45-53.

Research output: Contribution to journalReview article

@article{78d61df2d3dc44a5b302c98db7b37cbe,
title = "Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke",
abstract = "Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke. Evidence has demonstrated the important functions of these eicosanoids in regulating cerebral vascular tone, cerebral blood flow, and autoregulation of cerebral circulation. Although COX-2 inhibitors have been suggested as potential treatments for stroke, adverse events, including an increased risk of stroke, occur following long-term use of coxibs. It is important to note that prolonged treatment with rofecoxib increased circulating levels of 20-hydroxyeicosatetraenoic acid (20-HETE), and 20-HETE blockade is a possible strategy to prevent coxib-induced stroke events. It appears that 20-HETE has detrimental effects in the brain, and that its blockade exerts cerebroprotection against ischemic stroke and subarachnoid hemorrhage (SAH). There is clear evidence that activation of EP2 and EP4 receptors exerts cerebroprotection against ischemic stroke. Several elegant studies have contributed to defining the importance of stabilizing the levels of epoxyeicosatrienoic acids (EETs), by inhibiting or deleting soluble epoxide hydrolase (sEH), in stroke research. These reports support the notion that sEH blockade is cerebroprotective against ischemic stroke and SAH. Here, we summarize recent findings implicating these eicosanoid pathways in cerebral vascular function and stroke. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of ischemic stroke and SAH.",
keywords = "Cyclooxygenase, Cytochrome P450, Eicosanoids, Soluble epoxide hydrolase, Stroke",
author = "Hui Huang and Mohamed Al-Shabrawey and Mong-Heng Wang",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.prostaglandins.2015.12.007",
language = "English (US)",
volume = "122",
pages = "45--53",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke

AU - Huang, Hui

AU - Al-Shabrawey, Mohamed

AU - Wang, Mong-Heng

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke. Evidence has demonstrated the important functions of these eicosanoids in regulating cerebral vascular tone, cerebral blood flow, and autoregulation of cerebral circulation. Although COX-2 inhibitors have been suggested as potential treatments for stroke, adverse events, including an increased risk of stroke, occur following long-term use of coxibs. It is important to note that prolonged treatment with rofecoxib increased circulating levels of 20-hydroxyeicosatetraenoic acid (20-HETE), and 20-HETE blockade is a possible strategy to prevent coxib-induced stroke events. It appears that 20-HETE has detrimental effects in the brain, and that its blockade exerts cerebroprotection against ischemic stroke and subarachnoid hemorrhage (SAH). There is clear evidence that activation of EP2 and EP4 receptors exerts cerebroprotection against ischemic stroke. Several elegant studies have contributed to defining the importance of stabilizing the levels of epoxyeicosatrienoic acids (EETs), by inhibiting or deleting soluble epoxide hydrolase (sEH), in stroke research. These reports support the notion that sEH blockade is cerebroprotective against ischemic stroke and SAH. Here, we summarize recent findings implicating these eicosanoid pathways in cerebral vascular function and stroke. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of ischemic stroke and SAH.

AB - Arachidonic acid (AA) is metabolized by cyclooxygenase (COX) and cytochrome P450 (CYP) enzymes into eicosanoids, which are involved in cardiovascular diseases and stroke. Evidence has demonstrated the important functions of these eicosanoids in regulating cerebral vascular tone, cerebral blood flow, and autoregulation of cerebral circulation. Although COX-2 inhibitors have been suggested as potential treatments for stroke, adverse events, including an increased risk of stroke, occur following long-term use of coxibs. It is important to note that prolonged treatment with rofecoxib increased circulating levels of 20-hydroxyeicosatetraenoic acid (20-HETE), and 20-HETE blockade is a possible strategy to prevent coxib-induced stroke events. It appears that 20-HETE has detrimental effects in the brain, and that its blockade exerts cerebroprotection against ischemic stroke and subarachnoid hemorrhage (SAH). There is clear evidence that activation of EP2 and EP4 receptors exerts cerebroprotection against ischemic stroke. Several elegant studies have contributed to defining the importance of stabilizing the levels of epoxyeicosatrienoic acids (EETs), by inhibiting or deleting soluble epoxide hydrolase (sEH), in stroke research. These reports support the notion that sEH blockade is cerebroprotective against ischemic stroke and SAH. Here, we summarize recent findings implicating these eicosanoid pathways in cerebral vascular function and stroke. We also discuss the development of animal models with targeted gene deletion and specific enzymatic inhibitors in each pathway to identify potential targets for the treatment of ischemic stroke and SAH.

KW - Cyclooxygenase

KW - Cytochrome P450

KW - Eicosanoids

KW - Soluble epoxide hydrolase

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84952894974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952894974&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2015.12.007

DO - 10.1016/j.prostaglandins.2015.12.007

M3 - Review article

VL - 122

SP - 45

EP - 53

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

ER -